These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15651071)

  • 21. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
    Elkord E; Williams PE; Kynaston H; Rowbottom AW
    Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein.
    Mincheff M; Zoubak S; Altankova I; Tchakarov S; Pogribnyy P; Makogonenko Y; Botev C; Meryman HT
    Cancer Gene Ther; 2005 Feb; 12(2):185-97. PubMed ID: 15375382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice.
    Li X; Yang X; Jiang Y; Liu J
    Int Immunol; 2005 Oct; 17(10):1293-302. PubMed ID: 16113237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.
    Roos AK; Moreno S; Leder C; Pavlenko M; King A; Pisa P
    Mol Ther; 2006 Feb; 13(2):320-7. PubMed ID: 16185933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
    Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
    Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice.
    Pavlenko M; Leder C; Moreno S; Levitsky V; Pisa P
    Vaccine; 2007 Aug; 25(34):6341-7. PubMed ID: 17628235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response of established human breast tumors to vaccination with mammaglobin-A cDNA.
    Narayanan K; Jaramillo A; Benshoff ND; Campbell LG; Fleming TP; Dietz JR; Mohanakumar T
    J Natl Cancer Inst; 2004 Sep; 96(18):1388-96. PubMed ID: 15367572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.
    Klyushnenkova EN; Link J; Oberle WT; Kodak J; Rich C; Vandenbark AA; Alexander RB
    Clin Cancer Res; 2005 Apr; 11(8):2853-61. PubMed ID: 15837732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants.
    Kim JJ; Yang JS; Dang K; Manson KH; Weiner DB
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):882s-889s. PubMed ID: 11300487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inducement of cytotoxic T cell responses in mice by constructing a multi-CTL epitope-based DNA vaccine].
    Shi L; Yuan YK; Sheng L; Fan GX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):430-2. PubMed ID: 16806000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo.
    Tang XD; Wan Y; Chen L; Chen T; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
    Cancer Res; 2008 Mar; 68(5):1529-37. PubMed ID: 18316618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine.
    Xu W; Chu Y; Zhang R; Xu H; Wang Y; Xiong S
    Virology; 2005 Apr; 334(2):255-63. PubMed ID: 15780875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
    Samorski R; Gissmann L; Osen W
    Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.